Literature DB >> 12975751

Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.

William J Steinbach1, David A Stevens.   

Abstract

The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal. Previously there were only 2 antifungals with activity against Aspergillus, but over the last few years there has been an explosion of newer agents and reformulations of older antifungals. Exploration has also begun with immunotherapy, with use of cytokines and granulocyte transfusions alone or in combination with antifungal therapy. This review will detail the available in vitro, in vivo, and clinical experience with the newer antifungal and immunomodulatory therapies in development for treatment of invasive aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12975751     DOI: 10.1086/376523

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

1.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Authors:  William J Steinbach; Nina Singh; Jackie L Miller; Daniel K Benjamin; Wiley A Schell; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 2.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

3.  Detection of Aspergillus fumigatus and a mutation that confers reduced susceptibility to itraconazole and posaconazole by real-time PCR and pyrosequencing.

Authors:  Jason P Trama; Eli Mordechai; Martin E Adelson
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

Review 4.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

Review 5.  Immunosuppression related to collagen-vascular disease or its treatment.

Authors:  Carol Dukes Hamilton
Journal:  Proc Am Thorac Soc       Date:  2005

Review 6.  Will resistance in fungi emerge on a scale similar to that seen in bacteria?

Authors:  H Hof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

Review 7.  Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.

Authors:  Leah E Cowen; William J Steinbach
Journal:  Eukaryot Cell       Date:  2008-03-28

8.  Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

9.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Authors:  William J Steinbach; Wiley A Schell; Jill R Blankenship; Chiatogu Onyewu; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 10.  Management of invasive aspergillosis in patients with COPD: rational use of voriconazole.

Authors:  Florence Ader; Anne-Lise Bienvenu; Blandine Rammaert; Saad Nseir
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.